Targeted Updates project: Case Study A

Blog
Targeted Updates project: Case Study A

The Targeted Updates project aims to provide policy-makers, in particular guideline developers, with up-to-date information from Cochrane Reviews, tailored to their needs and working to a fast timeline.  Targeted Updates use Cochrane Reviews as their foundation, but focus on updating selected comparisons and outcomes, working in close consultation with key stakeholders. In this post, the team describes their first case study. For more information, please see the blog post introducing the Targeted Updates project.

Case Study A: Question identified in partnership with a Guideline Developer

1. Context
One of the first groups we worked with was the Skin Cochrane Review Group (CRG). We liaised with this CRG to identify priority topics for a Targeted Update (TU), based on their existing relationships with guidelines developers. Following consultation with these guideline developers, the CRG returned to us and suggested a number of topics that could be suitable for a TU. It was agreed that we would proceed with three of these topics: two produced by the TU team, and one produced by the CRG.

2. Process
We agreed the questions among the CRG, guideline developers, and the TU team. We began this process by liaising with the original Cochrane Review’s author team, who informed us that they were interested in beginning the process of updating the full review, and by conducting an initial assessment of the latest version of the full Cochrane Review. The CRG completed all tasks for one of the TUs internally, with guidance from the TU team. The TU team completed all tasks for two of the TUs, with content expertise from the CRG. The process of producing and peer reviewing these documents took much longer than expected. The first drafts of all three TUs were produced and ready for peer review within four months; the peer review of these documents was completed a further two months later.

3. Output
Targeted Updates led by TU team
Oral propranolol for infantile haemangioma

Topical timolol for infantile haemangioma

Targeted Update led by the CRG
Interventions for cutaneous sporotrichosis

4. Feedback from the Skin CRG
We asked the members of the Skin Group Editorial Team for some feedback on their experiences with the TU process, both positive and negative.

The team were pleased with the overall presentation of the final product, although they noted some areas in which improvements could still be made.

“I really liked the final product as it was easy to read in one bite. I had to check it over carefully though in order to get the messages and context right.”

“Could you have a separate section for quality assessment? I think the outcomes need stating clearly – you have to dig for them in the results and in the purple text on the 2nd page.”

“As a reader I think they are refreshingly clear and easy to understand, and the brevity is very welcome.”

One of the predominant disappointments experienced by the Skin CRG related to how long the entire process took, in comparison to what they had been told to expect.

I was disappointed about the time lag from completion of the TUs to publication, although I understand this may be due to this being a pilot.”

“I think originally the imposition of the tight timescale made it difficult to get started as it felt we had to drop everything to get these completed within weeks. So this timescale seemed to be totally unrealistic.

The team were also disappointed that the documents have yet to be made publically available.

“The fact that they are still not published in the public domain has completely defeated the purpose of doing them. I realise this will not be the case in the future.”

The Skin CRG were offered some monetary incentive to help complete the process. Overall, they seemed to find this a fair incentive.

“The funding seemed very fair to me. If we had that level of funding to employ systematic review help for other reviews, it would make a huge difference to us.”

We had hoped that sharing the updated searches with the group might also be a benefit for the group, but this may not have been the case.

“Not sure how valuable the search results were as we could probably handle that ourselves comfortably.”

“For me the process has been much as it would be for any other review as I have run the same searches I would have for a full review.  However, I’ve only had to run them once before publication of the finished product, rather than up to 4 or 5 times with our standard reviews, so that has felt very efficient.”

Overall, the team appreciated that, while the process may still have some issues to iron out, the overall concept is a good one that has its benefits and potential.

As a concept of how to update a big review by concentrating on the most important points of comparison it has potential.”

“It’s been a good catalyst for teams to get going on their full updates. I also think it facilitated more team thought into the topic area than there might have been if they’d gone ahead and began the update straightaway.”

5. Feedback from you
We are very interested to know what you think about these TU documents, and the project in general. We would really appreciate it if you could take just 5 minutes to read through and answer this short list of questions. Thank you very much for your participation!

6. Who are the team

Targeted Update team involved in production:

  • Rosie Asher
  • Hanna Bergman
  • Antonio Grande
  • Dennis Kahn
  • Rachel Marshall

Cochrane Review Authors:

  • Interventions for infantile haemangiomas
    • Monica Paola Novoa
    • Ingrid Arevalo-Rodriguez
    • Lucia Giraldo
    • Sandra Beltran
    • Eulalia Baselga
    • Ali Shahbaz
  • Interventions for the treatment of sporotrichosis
    • Jun Xia
    • Sai Zhao
    • Roderick Hay

CRG team:

  • Finola Delamere
  • Liz Doney
  • Laura Prescott
  • Hywel Williams

For more information

Email Nuala Livingstone, Cochrane Editorial Unit

 

14 June 2016

The Cochrane Official Blog is curated and maintained by the Development Directorate. To submit items for publication to the blog or to add comments to a blog, please email mumoquit@cochrane.org.

The Cochrane Blog presents commentary and personal opinion on topics of interest from a range of contributors to the work of Cochrane. Opinions posted on the Cochrane Blog are those of the individual contributors and do not necessarily reflect the views or policies of Cochrane.